期刊文献+

基质金属蛋白酶-9在冠心病心绞痛患者危险分层中的作用 被引量:3

Role of Matrix Metalloproteinase 9 in Risk Stratification of Patients with Angina Pectoris
下载PDF
导出
摘要 目的:研究基质金属蛋白酶-9(MMP-9)水平变化在心绞痛危险分层中的作用。方法:将161例连续行冠状动脉造影的患者根据MMP-9血清测定值四分位数法分成四组:A组≤108.2ng/ml,B组108.2~171.3ng/ml,C组171.3~239.8ng/ml,D组〉239.8ng/ml。观察各组临床事件、理化指标的差异;用多元逐步回归法计算MMP-9与多因素的相关性;比较A、B组与C、D组患者的6个月随访终点事件的累计发生率。结果:(1)不稳定型心绞痛(UAP)患者93.5%(58/62)分布于C、D组,与A、B组比较P〈0.001,其中59.7%(37/62)分布于D组,是A组的37倍(P〈0.001)。(2)C组的Gensini积分(49.3±12.5)最高,与A组(11.2±7.8)相比P〈0.001,与D组(37.5±12.4)比较P〈0.05。(3)血清MMP-9水平和hs-CRP水平呈正相关(r=0.65,P〈0.01)。MMP-9≤239.8ng/ml时MMP-9与Gensini积分呈正相关(r=0.53,P〈0.01),MMP-9〉239.8ng/ml时MMP-9与Gensini积分无相关性。(4)C、D组患者6个月随访心血管终点事件累计发生率明显高于A、B组(χ^2=14.8,P〈0.01)。结论:MMP-9在评价UAP患者斑块稳定性及在危险分层上可能是一个重要的生物学指标,尤其在识别高危的临界冠脉病变中可能有重要意义。 Objective:To investigate the role of matrix metalloproteinase 9(MMP-9) in risk stratification of patients with angina pectoris. Methods: 161 patients with angina pectoris underwent coronary angiography were divided into four groups according to quartile of MMP-9 level. Group A:≤108.2 ng/ml,group B:108.2~171.3 ng/ml,group C:〉 171. 3 ~ 239. 8 ng/ml,group D: 〉 239. 8 ng/ml. Relationship between MMP-9 and multi-elements was analyzed with multiple progressively regression and clinical endpoints within 6 months were observed. Results: (1) 93.5%(58/62) of patients with unstable angina pectoris(UAP) were in groups C and D, which was remarkable higher than the percentage in groups A and B(P〈0. 001). 59. 7%(37/62) of patients with UAP were in group D,37 folds of the percentage in group A(P〈0. 001). (2) Gensini Score(49. 3±12. 5) in group C was highest,significantly higher than the Score of group A(P%0.001) and group D(P〈.05). (3)MMP-91evel positively correlated with hs-CRP level(r=0.65,P〈 0. 01). It also positively correlated with Gensini Score(r=0.53,P〈0. 01) while MMP-9 level was lower than 239, 8ng/ ml ,however,no correlation was observed while MMP-9 level was higher than 239.8ng/ml. (4) Cumulative incidence of clinical endpolnts within 6 months was statistically different between MMP-9≤171.3 ng/ml group and 〉171.3 ng/ml group (χ^2= 14.8,P% 0. 01). Conclusion: MMP-9 level may be an important biomarker in assessment of atherosclerotic plaque stability and risk stratification in UAP patients, especially in identification of high-risk intermediate coronary stenosis patients.
出处 《中国误诊学杂志》 CAS 2008年第9期2017-2020,共4页 Chinese Journal of Misdiagnostics
关键词 明胶酶B/血液/诊断应用 心绞痛/代谢/诊断 人类 Gelatinase B/blood/diagnostic use Angina Pectoris/metabolism/diagnosis Humans
  • 相关文献

参考文献8

  • 1Manginas A,Bei E,Chaidaroglou A,et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I[J]. Clin Cardiol,2005,28(4):182-186. 被引量:1
  • 2Johnson JL, Fritsche-Danielson R, Behrendt M, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability[J ]. Cardiovasc Res, 2006,71 (3) : 586-595. 被引量:1
  • 3Chen F,Eriksson P,Hansson GK ,et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque[J], Int J Mol Med, 2005,15 ( 1 ) : 57-65. 被引量:1
  • 4Gensini GG, A more meaningful scoring system for determining the severity of coronary heart disease [J], Am J Cardiol, 1983,51 (3) : 606-608. 被引量:1
  • 5Arno G, Kaski JC, Smith DA, et al. Matrix metalloproteinase 9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques[J]. Heart, 2005, 91(4) :521-525. 被引量:1
  • 6Papalambros E,Sigala F,Georgopoulos S,et al. Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization[J]. Cerebrovase Dis, 2004, 18(2):160-165. 被引量:1
  • 7Sawada T ,Shite J ,Shinke T,et al. Relationship between high sensitive C-reactive protein and coronary plaque component in patients with acute coronary syndrome: Virtual Histology study [J].J Cardiol,2006,48(3):141-150. 被引量:1
  • 8Bech G J, De Bruyne B,Pijls NH,et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis : a randomized trial[J]. Circulation, 2001,103 ( 24 ) : 2928-2934. 被引量:1

同被引文献23

  • 1赵慧颖,徐宝华,马小欣.血清基质金属蛋白酶活性与动脉粥样硬化斑块稳定性的实验观察[J].中国微循环,2007,11(3):163-167. 被引量:16
  • 2Johnson JL,Fritsehe-Danielson R, Behrendt M, et al.Effeet of broad spectrum matrix metall0prOteinase inhibition on atherosclerotic plaque stability [J]. Cardiovasc Res, 2006, 71(3): 586-595. 被引量:1
  • 3Manginas A, Bei E, Chaidaroglou A, et al. Peripheral levels of matrix metalloproteinase -9,interleukin -6,and C-reactive protein are elevated in patients with acute coronary syndromes:correlations with serum troponin I [J]. Clin Cardiol,2005, 28(4): 182-186. 被引量:1
  • 4Chen F, Eriksson P, Hansson GK, et al.Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque [J]. Int J Mol Med, 2005, 15(1): 57-65. 被引量:1
  • 5Heeneman S, Cleutjens JP, Faber BC, et al. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol, 2003,200 (4) : 516-525. 被引量:1
  • 6Morishige K, Shimokawa H, Matsumoto Y, et al. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc Res, 2003,57(2):572-585. 被引量:1
  • 7Morgan AR, Zhang B, Tapper W, et al. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med ( Berl), 2003,81 (5) : 321-326. 被引量:1
  • 8Blankenberg S, Rupprecht H J, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003,107(12) : 1579-1585. 被引量:1
  • 9Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation, 2004,110(13) : 1747-1753. 被引量:1
  • 10Heeneman S,Cleutjens JP,Faber BC. The dynamic extracellular matrix intervention strategies during heart failure and and at herosclerosis[J].Journal of Pathology,2003.516-525. 被引量:1

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部